Drugmaker Declines FDA Request to Pull Treatment After Patient Deaths

Last updated: July 22, 2025 9:48 am

1 Min Read

Drugmaker Declines FDA Request to Pull Treatment After Patient Deaths

The U.S. Food and Drug Administration (FDA) in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

Sarepta Therapeutics will not agree to a regulatory request to pause shipments of a treatment for muscular dystrophy in the wake of patient deaths, the pharmaceutical company said on July 18 after receiving the request.

“Based on our comprehensive scientific interpretation of the data, which shows no new or changed safety signals in the ambulant patient population, we will continue to ship Elevidys to the ambulant population,” Sarepta said in a statement.